The role of prophylactic cranial irradiation (PCI) in the management o
f patients with small cell lung cancer is reviewed, with emphasis on 1
1 randomised trials. Several interpretive and methodological problems
related to PCI investigations are identified, and it is argued that gi
ven the current data PCI should be considered as an optional treatment
component in CR patients, that these authors do not recommend, while
other investigators do.